文献速递创伤与烧伤重症综合管理与镇静镇痛

苯巴比妥预防创伤患者酒精戒断的评估

Evaluation of phenobarbital for prevention of alcohol withdrawal in trauma patients.
PubMed 文献 · J Trauma Acute Care Surg · 2023-06-15
一句话结论创伤患者用苯巴比妥预防酒精戒断,需补救治疗更少(16% vs 62%),无低血压发生,但住院时间更长。

该研究纳入2019年1月至2021年8月在一级创伤中心接受至少一剂苯巴比妥预防酒精戒断综合征(AWS)的成年患者,按AWS风险与症状触发治疗对照组进行病例匹配,每组55例。苯巴比妥组补救治疗需求更低(16% vs 62%,p<0.001),补救治疗时间更长(26 vs 11小时,p=0.01),住院时间更长(216 vs 87小时,p=0.0001),ICU住院时间无差异(p=0.36)。两组均无震颤谵妄或癫痫发作,插管率无差异(p=0.68),苯巴比妥组无低血压发生。作者认为需进一步研究创伤人群预防酒精戒断的方案。

要点

  • 苯巴比妥组补救治疗需求16% vs 对照组62%(p<0.001),补救治疗时间26 vs 11小时(p=0.01)。
  • 苯巴比妥组住院时间216 vs 87小时(p=0.0001),ICU住院时间无差异(p=0.36)。
  • 两组均无震颤谵妄或癫痫发作,插管率无差异(p=0.68),苯巴比妥组无低血压发生。
  • 苯巴比妥组基线损伤严重度评分更高(p=0.03),ICU入住率44% vs 24%(p=0.03)。
  • 作者认为需进一步研究创伤人群预防酒精戒断的方案。

适用人群与场景

  • 2019年1月至2021年8月在一级创伤中心接受至少一剂苯巴比妥预防AWS的成年患者。
  • 对照组为基于AWS风险进行症状触发治疗的患者,按性别、年龄、AWS/震颤谵妄或戒断癫痫发作史、选定实验室值和筛查问卷进行病例匹配。

处置流程与药物剂量

  • 苯巴比妥用于预防AWS,至少一剂;原文未写明具体剂量、给药途径和频次。
  • 对照组采用症状触发治疗。

研究设计与关键结果

  • 研究类型为病例匹配研究,共纳入110例患者,每组55例;苯巴比妥组基线损伤严重度评分更高(p=0.03),ICU入住率44% vs 24%(p=0.03)。
  • 主要终点:苯巴比妥组补救治疗需求16% vs 对照组62%(p<0.001)。
  • 次要终点:补救治疗时间26 vs 11小时(p=0.01);住院时间216 vs 87小时(p=0.0001);ICU住院时间无差异(p=0.36)。
  • 两组均无震颤谵妄或癫痫发作,插管率无差异(p=0.68);苯巴比妥组无低血压发生。

证据类型、等级与局限

  • 证据类型:治疗/护理管理研究,证据等级III级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,使用苯巴比妥管理的患者AWS补救治疗需求更低,且未增加不良事件。
  • 作者认为,需进一步研究创伤人群预防酒精戒断的方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Up to 30% of trauma patients experience alcohol withdrawal syndrome (AWS) during their hospital admission, which is associated with worse outcomes. While benzodiazepines and phenobarbital are the mainstay of AWS management, there are limited data on the prevention of AWS. The objective was to evaluate the safety and efficacy of phenobarbital for the prevention of AWS.

METHODS: Adult patients admitted to a level 1 trauma center who received at least one dose of phenobarbital for the prevention of AWS between January 2019 and August 2021 were included. Patients were case matched to a control group managed with symptom-triggered therapy based on risk of AWS. Risk factors included sex, age, history of AWS/delirium tremens or withdrawal seizures, selected laboratory values, and screening questionnaires. The primary endpoint was the need for rescue therapy. Secondary endpoints included the time to rescue therapy, intensive care unit (ICU) length of stay (LOS), and hospital LOS.

RESULTS: Overall, 110 patients were included with 55 patients in each group. The phenobarbital group had higher baseline Injury Severity Scores ( p = 0.03) and were more likely to be admitted to the ICU (44% vs. 24%; p = 0.03). The phenobarbital group required less rescue therapy (16% vs. 62%; p < 0.001) with a longer time to rescue therapy administration (26 vs. 11 hours; p = 0.01). The phenobarbital group had a longer hospital LOS (216 vs. 87 hours; p = 0.0001) but no difference in ICU LOS ( p = 0.36). There was no incidence of delirium tremens or seizures and no difference in intubation rates ( p = 0.68). There was no incidence of hypotension associated with phenobarbital.

CONCLUSION: Patients managed with phenobarbital had a lower need for rescue therapy for AWS with no increased adverse effects. Further studies should evaluate a protocol to prevent alcohol withdrawal in the trauma population.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Kip LM, Forni A, Dorfman JD, et al. Evaluation of phenobarbital for prevention of alcohol withdrawal in trauma patients. J Trauma Acute Care Surg. 2023. PMID: 37418690. doi:10.1097/TA.0000000000004039

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。